AlzeCure Pharma AB (publ) has, prior to its listing on Nasdaq First North Premier, completed a new share issue of approximately SEK 200 million before issue costs.
The new share issue generated strong interest and was heavily oversubscribed. Estimated first day of trading in AlzeCure's share on Nasdaq First North Premier is 28 November 2018.
AlzeCure Pharma is a Swedish pharmaceutical research and development company developing innovative and effective drugs for the treatment of brain disease, with a primary focus on Alzheimer’s disease.
Vator Securites AB acted as Sole Global Coordinator, Bookrunner and financial advisor in the transaction. Baker McKenzie acted as legal adviser to Vator Securities. Baker McKenzie's team consisted mainly of Joakim Falkner, Stefan Balazs and Ian Gulam.